Convergent Pharmaceuticals

Convergent Therapeutics is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for the treatment of cancer. The company's lead program, CONV01-α, is a monoclonal antibody conjugated with actinium-225 (225Ac), a potent alpha-emitting radioisotope, specifically designed to target prostate-specific membrane antigen (PSMA). By utilizing a functional antibody rather than a small molecule ligand, Convergent aims to improve the delivery and retention of radioactive payloads within tumor cells while minimizing off-target effects. The company is currently advancing its pipeline through clinical trials for metastatic castration-resistant prostate cancer (mCRPC).